Bdnf Neurotrophic Factor Biomarker is a biomarker relevant to neurodegenerative disease diagnosis and research. This page provides detailed information about its characteristics, detection methods, and clinical significance.
Category: Biomarker
Target: BDNF protein
Sample Type: Blood (plasma/serum), CSF
Diseases: Alzheimer's Disease, Parkinson's Disease, Depression, Rett Syndrome, Huntington's Disease, Schizophrenia
Direction: Decreased in neurodegeneration (typically)
Sensitivity: pg/mL range in blood
Brain-Derived Neurotrophic Factor (BDNF) is the most abundant neurotrophin in the brain and plays critical roles in neuronal survival, synaptic plasticity, memory formation, and cognitive function. BDNF is essential for hippocampal long-term potentiation (LTP) and is heavily implicated in neurodegenerative diseases and psychiatric disorders[1]. Circulating BDNF levels reflect brain BDNF activity to some degree, making it a valuable biomarker for neuronal health and therapeutic response.
| Property | Value |
|---|---|
| Gene | BDNF |
| Protein | Brain-Derived Neurotrophic Factor |
| UniProt | P23560 |
| Molecular Weight | 13 kDa (dimer: 26 kDa) |
| Expression | Brain (hippocampus, cortex), peripheral nervous system |
| Receptor | TrkB (NTRK2), p75^NTR |
| Function | Neuronal survival, synaptic plasticity, LTP |
The BDNF gene is located on chromosome 11p14.1 and contains 11 exons that undergo alternative splicing, producing multiple transcripts with distinct expression patterns[2]. The protein is synthesized as a precursor (pro-BDNF, ~32 kDa) that is cleaved to mature BDNF (∼13 kDa). Both forms are biologically active but signal through different receptors:
The Val66Met polymorphism (rs6265) in the BDNF gene affects activity-dependent secretion and is associated with altered cognitive function and increased risk of depression[3].
When mature BDNF binds to TrkB (tropomyosin receptor kinase B), it triggers multiple downstream signaling cascades:
The p75 neurotrophin receptor can signal pro-apoptotic pathways when bound by pro-BDNF, mediating developmental neuronal death and synaptic pruning[4]. This highlights the delicate balance between pro-BDNF and mature BDNF in brain homeostasis.
BDNF plays a particularly important role in Alzheimer's disease (AD) pathogenesis. Reduced serum and CSF BDNF levels correlate with cognitive impairment and disease severity[5]. The relationship is bidirectional:
Exercise increases BDNF production, which may explain the cognitive benefits of physical activity in AD[6]. Additionally, several AD therapeutics may work partially through BDNF upregulation, including GLP-1 receptor agonists.
In Parkinson's disease (PD), BDNF is critical for dopaminergic neuron survival. Reduced serum and CSF BDNF levels correlate with motor severity (UPDRS score) and disease progression[7]. The nigrostriatal pathway depends on BDNF for maintenance of dopaminergic neurons, and BDNF delivery has been explored as a neuroprotective strategy.
Huntington's disease (HD) is characterized by dramatically reduced BDNF levels in the striatum and cortex. The mutant huntingtin protein impairs BDNF transcription and transport, contributing to selective neuronal vulnerability[8]. BDNF levels correlate inversely with CAG repeat length and disease severity.
ALS patients show decreased serum BDNF, and the decline correlates with disease progression. BDNF has been investigated as a neuroprotective therapy, though delivery challenges have limited clinical translation.
MSA patients demonstrate reduced CSF BDNF levels, potentially reflecting oligodendroglial and neuronal dysfunction. The biomarker utility in differential diagnosis is still being evaluated.
| Disease | BDNF Level | Correlation | Utility |
|---|---|---|---|
| AD | Decreased | Cognitive score, hippocampal volume | Monitoring |
| PD | Decreased | Motor severity (UPDRS) | Monitoring |
| Depression | Decreased | Severity, treatment response | Biomarker |
| HD | Decreased | Disease stage, CAG length | Monitoring |
| Rett | Severely decreased | Severity | Target |
BDNF serves as a pharmacodynamic biomarker for:
Several approaches are being developed to enhance BDNF signaling[9]:
The study of Bdnf Neurotrophic Factor Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| Sample Type | Normal Range | Notes |
|---|---|---|
| Serum | 20-40 ng/mL | Variable by assay |
| Plasma | 5-20 pg/mL | Platelets affect levels |
| CSF | 10-50 pg/mL | More stable |
Egan MF, et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion. Cell. ↩︎
Pruunsild P, et al. (2007). Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics. ↩︎
Bath KG, Lee FS (2010). Variant BDNF (Val66Met) impact on brain structure and function. Cogn Neuropsychiatry. ↩︎
Teng HK, et al. (2005). ProBDNF induces neuronal apoptosis via the p75NTR pathway. Exp Neurol. ↩︎
Li B, et al. (2022). Brain-derived neurotrophic factor in Alzheimer's disease: risk, mechanisms, and therapeutic targeting. Prog Neuropsychopharmacol Biol Psychiatry. ↩︎
Cotman CW, Berchtold NC (2002). Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. ↩︎
Salehi Z, Mashayekhi F (2009). Brain-derived neurotrophic factor serum concentrations in Parkinson's disease. J Neurol Sci. ↩︎
Zuccato C, Cattaneo E (2009). Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. ↩︎
Nagahara AH, Tuszynski MH (2011). Potential of neurotrophic factors for repair of brain injury. Nature. ↩︎